ClinicalTrials.gg
CompletedNCT04293458ESOGUARDBE1Updated Jan 25, 2023

Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE

An interventional study of EsoGuard in Barrett Esophagus, Esophageal Adenocarcinoma and Barretts Esophagus With Dysplasia, sponsored by Lucid Diagnostics, Inc.. Completed at 27 sites in 2 countries. Open to male participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-25.

Sponsored by Lucid Diagnostics, Inc. · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
145
Allocation
Not applicable
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 209 studies in Barrett Esophagus with a site in United States — 38 open to participants now, 48 under way, none of them phase 3. Barrett Esophagus · United States.

Enrollment
26th of 122
145 · median 58
Started
2020
with 8 others
No phase
78 of 209
13 open now
Registered
166th of 209
by date
Lead sponsor
5 of 209
Lucid Diagnostics, Inc.

Among the 209 studies in Barrett Esophagus with a site in United States, this one is the 26th largest by enrollment of the 122 interventional ones that give a count, is one of 9 that started in 2020, is one of 78 with no phase, and was the 166th registered.

Barrett Esophagus

312 studies on the registry are indexed under Barrett Esophagus; 60 are open to participants now.

Browse Barrett Esophagus studies →

Open to participants now

38 of the 209 studies in Barrett Esophagus with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Barrett Esophagus studies recruiting now, 31 (70%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 50 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Barrett Esophagus with a site in United States, or all of them as a file.
02

Study summary

The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay on cells collected using the EsoCheck 510(k) cleared device, to detect Barrett's Esophagus, with and without dysplasia, and/or Esophageal Adenocarcinoma, in individuals deemed to be at high risk for these conditions (i.e., screening) per ACG guidelines.

Read the detailed description

This is a multicenter, single-arm study designed to assess the operating characteristics of the EsoGuard diagnostic assay performed on distal esophageal mucosal cells collected using the EsoCheck cell collection device, compared to the gold standard, for the screening of BE with and without dysplasia and for esophageal adenocarcinoma (EAC), in patients at high risk for BE and for whom a screening EGD is indicated according to ACG-established criteria.

03

Conditions studied

  • Barrett Esophagus
  • Esophageal Adenocarcinoma
  • Barretts Esophagus With Dysplasia
  • Barrett's Esophagus Without Dysplasia
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men aged 50 years old and older
  2. ≥5 years either of

    • GERD symptoms,
    • GERD treated with proton pump inhibitor (PPI) therapy (whether symptom control is achieved or not), or,
    • any combination of treated and untreated periods, as long the cumulative total is at least 5 years
  3. No solid foods eaten for at least 2 hours prior to EsoCheck procedure
  4. One or more of the following risk factors:

    1. Caucasian race
    2. Current or past history of cigarette smoking
    3. of at least 30 kg/m2
    4. First-degree relative with BE or EAC

Exclusion criteria

-

Exclusion Criteria:

  1. History of prior EGD procedure
  2. Inability to provide written
  3. On anti-coagulant drug(s) that cannot be temporarily discontinued
  4. Known history of esophageal varices or esophageal stricture
  5. Any , as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and/or having taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and/or esophageal ulceration
  6. History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills
  7. Oropharyngeal tumor
  8. History of esophageal or gastric surgery, with exception of uncomplicated surgical fundoplication procedure
  9. History of myocardial infarction or cerebrovascular accident within past 6 months
  10. History of esophageal motility disorder
  11. Currently implanted Linx device
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    EsoCheck vs. EGD with or without biopsies

    All subjects will undergo both the EsoCheck (non-invasive esophageal cell sample collection) followed by EGD (with or without biopsies)

    Device: EsoGuard

Interventions

  • DeviceEsoGuard

    EsoGuard assay (LDT) will be used on cells collected using EsoCheck (510K cleared esophageal cell collection device) and compared to results of EGD plus biopsies (when taken)

06

What researchers measure

Primary outcomes

  1. Primary Efficacy

    The sensitivity and specificity of EsoGuard for the diagnosis of BE on samples collected using EsoCheck, wherein the definitive diagnosis of BE is made by concomitant EGD and biopsy.

    Time frame: Cross-sectional point in time per subject through study completion which is up to approximately 5 weeks

Secondary outcomes

  1. Secondary Efficacy

    Negative predictive value (NPV) and positive predictive value (PPV), calculated for the observed prevalence and over a range of prevalences from 1 to 15%.

    Time frame: Cross-sectional point in time per subject through study completion which is up to approximately 5 weeks

Other outcomes

  1. Safety of EsoCheck device administration

    Assessed by evaluation of AEs/SAEs/ADEs/SADEs/USADEs and Medical Device Deficiency Incidents

    Time frame: Cross-sectional point in time per subject through study completion which is up to approximately 5 weeks

07

Study locations

27 sites
  • Lucid Investigative Site
    Orange, California 92868, United States
  • Lucid Investigative Site
    Englewood, Colorado 80113, United States
  • Lucid Investigative Site
    Naples, Florida 34102, United States
  • Lucid Investigative Site
    Palm Harbor, Florida 34684, United States
  • Lucid Investigative Site
    Macon, Georgia 31201, United States
  • Lucid Investigative Site
    Idaho Falls, Idaho 83404, United States
  • Lucid Investigative Site
    Rockford, Illinois 61107, United States
  • Lucid Investigative Site
    New Orleans, Louisiana 70112, United States
  • Lucid Investigative Site
    Shreveport, Louisiana 71105, United States
  • Lucid Investigative Site
    Wyoming, Michigan 49519, United States
  • Lucid Investigative Site
    Flowood, Mississippi 39232, United States
  • Lucid Investigative Site
    Omaha, Nebraska 68124, United States
  • Lucid Investigative Site
    New York, New York 10016, United States
  • Lucid Investigative Site
    Rochester, New York 14620, United States
  • Lucid Investigative Site
    Chapel Hill, North Carolina 27599, United States
  • Lucid Investigative Site
    Oklahoma City, Oklahoma 73102, United States
  • Lucid Investigative Site
    Philadelphia, Pennsylvania 19107, United States
  • Lucid Investigative Site
    Greenville, South Carolina 29615, United States
  • Lucid Investigative Site
    Knoxville, Tennessee 37909, United States
  • Lucid Investigative Site
    Nashville, Tennessee 37212, United States
  • Lucid Investigative Site
    Houston, Texas 77030, United States
  • Lucid Investigative Site
    Salt Lake City, Utah 84132, United States
  • Lucid Investigative Site
    Richmond, Virginia 23249, United States
  • Lucid Investigative Site
    Richmond, Virginia 23298, United States
  • Lucid Investigative Site
    Madrid, 28040, Spain
  • Lucid Investigative Site
    Valladolid, 47012, Spain
  • Lucid Investigative Site
    Zaragoza, 50009, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Aug 2022, 29 months.

Of 76 interventional studies with no phase under Barrett Esophagus, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 108. This study's 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2020
First posted
Mar 3, 2020
StartActual
Feb 28, 2020
Primary completionActual
Aug 22, 2022
CompletionActual
Aug 22, 2022
Last update
Jan 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04293458
Lead sponsor
Lucid Diagnostics, Inc.
Responsible party
Sponsor
First posted
Mar 3, 2020
Start date
Feb 28, 2020
Primary completion
Aug 22, 2022
Completion
Aug 22, 2022
Last update
Jan 25, 2023

Study contacts

Michelle McDermott
study director · Lucid Diagnostics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion